請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/104669完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 吳亞克 | zh_TW |
| dc.contributor.advisor | Andrei R. Akhmetzhanov | en |
| dc.contributor.author | 謝昇諺 | zh_TW |
| dc.contributor.author | Sheng-Yen Hsieh | en |
| dc.date.accessioned | 2026-08-31T16:12:06Z | - |
| dc.date.available | 2026-09-01 | - |
| dc.date.copyright | 2026-08-31 | - |
| dc.date.issued | 2026 | - |
| dc.date.submitted | 2026-08-05 00:00:00 | - |
| dc.identifier.citation | 1. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. 2020;584(7820):257–61. doi:·10.1038/s41586-020-2405-7
2. Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, et al. Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav. 2020;4(12):1303–12. doi:·10.1038/s41562-020-01009-0 3. Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, et al. Decreased Influenza Activity During the COVID-19 Pandemic - United States, Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(37):1305–9. doi:·10.15585/mmwr.mm6937a6 4. Groves HE, Piche-Renaud PP, Peci A, Farrar DS, Buckrell S, Bancej C, et al. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study. Lancet Reg Health Am. 2021;1:100015. doi:·10.1016/j.lana.2021.100015 5. Lee PI, Hsueh PR, Chuang JH, Liu MT. Changing epidemic patterns of infectious diseases during and after COVID-19 pandemic in Taiwan. J Microbiol Immunol Infect. 2024;57(5):685–90. doi:·10.1016/j.jmii.2024.07.002 6. Baker RE, Park SW, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. The impact of COVID-19 nonpharmaceutical interventions on the future dynamics of endemic infections. Proc Natl Acad Sci U S A. 2020;117(48):30547–53. doi:·10.1073/pnas.2013182117 7. Cohen R, Ashman M, Taha MK, Varon E, Angoulvant F, Levy C, et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now. 2021;51(5):418–23. doi:·10.1016/j.idnow.2021.05.004 8. Park SW, Holmdahl I, Howerton E, Yang W, Baker RE, Vecchi GA, et al. Interplay between climate and childhood mixing can explain a sudden shift in RSV seasonality in Japan. Nat Commun. 2025;16(1):11385. doi:·10.1038/s41467-025-66184-y 9. Russcher A, van Boven M, Beninca E, Verweij E, Molenaar-de Backer MWA, Zaaijer HL, et al. Changing epidemiology of parvovirus B19 in the Netherlands since 1990, including its re-emergence after the COVID-19 pandemic. Sci Rep. 2024;14(1):9630. doi:·10.1038/s41598-024-59582-7 10. Motomura Y, Takemoto R, Yamamura K, Nagata H, Miyata T, Yoshizato R, et al. Clinical and virological impacts of human parvovirus B19 epidemics on fulminant myocarditis in childhood. BMC Pediatr. 2026;26(1):127. doi:·10.1186/s12887-025-06502-x 11. Taiwan Centers for Disease Control. Laboratory-based Automated Reporting System (LARS) Taipei: Taiwan Centers for Disease Control; [Available from: https://nidss.cdc.gov.tw/misc/lars?id=uri. 12. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917–28. doi:·10.1056/NEJM200106213442507 13. Shi T, McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58. doi:·10.1016/S0140-6736(17)30938-8 14. Nagasawa K, Ishiwada N. Disease burden of respiratory syncytial virus infection in the pediatric population in Japan. J Infect Chemother. 2022;28(2):146–57. doi:·10.1016/j.jiac.2021.11.007 15. Bloom-Feshbach K, Alonso WJ, Charu V, Tamerius J, Simonsen L, Miller MA, et al. Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. PLoS One. 2013;8(2):e54445. doi:·10.1371/journal.pone.0054445 16. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodriguez-Tenreiro C, Sly P, Ramilo O, et al. Respiratory Syncytial Virus Seasonality: A Global Overview. J Infect Dis. 2018;217(9):1356–64. doi:·10.1093/infdis/jiy056 17. Pitzer VE, Viboud C, Alonso WJ, Wilcox T, Metcalf CJ, Steiner CA, et al. Environmental drivers of the spatiotemporal dynamics of respiratory syncytial virus in the United States. PLoS Pathog. 2015;11(1):e1004591. doi:·10.1371/journal.ppat.1004591 18. Ogimi C, Ikuse T, Aizawa Y, Takanashi S. Current Challenges and Future Directions for RSV Prevention Strategies in Japan. Pediatr Infect Dis J. 2025;44(11):e400–e6. doi:·10.1097/INF.0000000000004936 19. Young NS, Brown KE. Parvovirus B19. New England Journal of Medicine. 2004;350(6):586–97. doi:·10.1056/NEJMra030840 20. Heegaard ED, Brown KE. Human Parvovirus B19. Clinical Microbiology Reviews. 2002;15(3):485–505. doi:·10.1128/cmr.15.3.485-505.2002 21. Servey JT, Reamy BV, Hodge J. Clinical presentations of parvovirus B19 infection. Am Fam Physician. 2007;75(3):373–6. 22. National Institute of Infectious Diseases. Infectious Diseases Weekly Report (IDWR): National Institute of Infectious Diseases; [Available from: https://idsc.niid.go.jp/idwr/index.html. 23. Anderson RM, May RM. Infectious diseases of humans: Dynamics and control: Oxford University Press; 1991. 24. Keeling MJ, Rohani P. Modeling infectious diseases in humans and animals: Princeton University Press; 2008. 25. Torrence C, Compo GP. A Practical Guide to Wavelet Analysis. Bulletin of the American Meteorological Society. 1998;79(1):61–78. doi:·10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2 26. Statistics of Tokyo. WEB infection incidence trend survey: Tokyo Metropolitan Institute of Public Health; [Available from: https://survey.tmiph.metro.tokyo.lg.jp/epidinfo/. 27. Statistics of Tokyo. Tokyo Statistical Yearbook: Statistics Division, Bureau of General Affairs; [Available from: https://www.toukei.metro.tokyo.lg.jp/tnenkan/tn-eindex.htm. 28. Statistics of Tokyo. Population Trends (Yearly): Table 1. Population (Total) by Ward, City, and Municipality, by Factor of Change: Statistics Division, Bureau of General Affairs; [Available from: https://www.toukei.metro.tokyo.lg.jp/tnenkan/tn-eindex.htm. 29. Statistics of Tokyo. Tokyo Statistical Yearbook: Deaths by Single Years of Age and Gender Tokyo: Statistics Division, Bureau of General Affairs; [Available from: https://www.toukei.metro.tokyo.lg.jp/tnenkan/tn-eindex.htm. 30. Taiwan Ministry of the Interior. Population Statistics Database: Department of Household Registration; [Available from: https://www.ris.gov.tw/app/portal/346. 31. Griffiths C, Drews SJ, Marchant DJ. Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment. Clin Microbiol Rev. 2017;30(1):277–319. doi:·10.1128/CMR.00010-16 32. Gelman A. Prior distributions for variance parameters in hierarchical models (Comment on Article by Browne and Draper). Bayesian Analysis. 2006;1(3):515–34. doi:·10.1214/06-BA117A 33. Stan Development Team. CmdStanR: R interface to CmdStan. 34. Hoffman MD, Gelman A. The No-U-Turn sampler: Adaptively setting path lengths in Hamiltonian Monte Carlo. Journal of Machine Learning Research. 2014;15:1593–623. 35. Carpenter B, Gelman A, Hoffman MD, Lee D, Goodrich B, Betancourt M, et al. Stan: A probabilistic programming language. Journal of Statistical Software. 2017;76(1):1–32. doi:·10.18637/jss.v076.i01 36. Vehtari A, Gelman A, Simpson D, Carpenter B, Bürkner PC. Rank-normalization, folding, and localization: An improved R-hat for assessing convergence of MCMC. Bayesian Analysis. 2021;16(2):667–718. doi:·10.1214/20-BA1221 37. Gouhier TC, Grinsted A, Simko V. biwavelet: Conduct univariate and bivariate wavelet analyses. 2021. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/104669 | - |
| dc.description.abstract | 2019 年底開始的 COVID-19 爆發,促使包括臺灣與日本在內的東亞國家採取了嚴格的非藥物介入措施(non-pharmaceutical interventions, NPIs),如口罩強制令、社交距離限制及邊境管制等政策。儘管這些措施有效抑制了 SARS-CoV-2 的傳播,也同時降低了其他常見呼吸道病毒的傳播,使原本透過反覆季節性暴露所維持的群體免疫受到影響。由此產生的易感人群累積,即所謂的「免疫負債」(immunity debt),被認為是非藥物介入措施解除後多種呼吸道病毒出現異常大規模再流行的重要驅動因素。
為探討免疫負債對不同呼吸道病毒再流行的影響,本研究以呼吸道融合病毒(Respiratory Syncytial Virus, RSV)感染症及由人類微小病毒 B19(Parvovirus B19)引起的傳染性紅斑(第五病)為研究對象。利用日本與臺灣過去十年間的傳染病監測資料建立傳播模型,其中日本資料包含年齡分層病例資訊。RSV 採用 SIRS(易感–感染–康復–易感)模型,傳染性紅斑則採用 SIR(易感–感染–康復)模型,以描述兩種疾病不同的免疫特性及傳播動態。 模型分析結果顯示,COVID-19 疫情期間非藥物介入措施導致兩種疾病的易感人群皆明顯累積,但其疫情再流行模式存在顯著差異。RSV 在防疫措施放寬後迅速恢復流行,而傳染性紅斑則於數年後才出現延遲且大規模的疫情再流行,顯示免疫特性與傳播週期共同影響疫情恢復的時機與規模。此外,臺灣與日本的 RSV 亦呈現不同的疫情恢復軌跡,反映不同防疫政策及流行病學背景對病毒傳播動態的影響。 本研究支持免疫負債為 COVID-19 後病毒再流行的重要機制之一,並顯示不同病原體因免疫持續時間及傳播特性的差異,可能產生不同的疫情恢復模式,研究結果可作為未來公共衛生防疫策略規劃及地方性傳染病監測的重要參考。 | zh_TW |
| dc.description.abstract | The emergence of COVID-19 in late 2019 prompted East Asian countries, including Taiwan and Japan, to implement stringent non-pharmaceutical interventions (NPIs), such as mandatory masking, social distancing, and border control. While these measures effectively reduced the transmission of SARS-CoV-2, they also suppressed the circulation of other common respiratory viruses that normally maintain population immunity through repeated seasonal exposure. The resulting accumulation of susceptible individuals, referred to as immunity debt, has been proposed as an important driver of the unusually large post-pandemic resurgence of multiple respiratory viruses following the relaxation of NPIs.
To investigate the impact of immunity debt on the post-pandemic resurgence of respiratory viruses, this study focused on respiratory syncytial virus (RSV) infection and erythema infectiosum (fifth disease) caused by human parvovirus B19. Surveillance data collected over the past decade from Japan and Taiwan were analyzed to develop compartmental transmission models, with age-stratified case data available for the Japanese surveillance system. An SIRS (Susceptible–Infected–Recovered–Susceptible) compartmental model was developed for RSV, whereas a SIR (Susceptible–Infected–Recovered) compartmental model was used for erythema infectiosum to reflect their distinct immunological characteristics. Model analyses showed that susceptible individuals accumulated substantially for both diseases during the COVID-19 pandemic because of reduced viral transmission; however, their post-pandemic resurgence patterns differed markedly. RSV rapidly resumed circulation following the relaxation of NPIs, whereas erythema infectiosum exhibited a delayed but pronounced resurgence several years later, suggesting that differences in immune characteristics and epidemic periodicity jointly influenced the timing and magnitude of epidemic recovery. In addition, RSV epidemics in Taiwan and Japan followed distinct recovery trajectories, highlighting the influence of different public health policies and epidemiological settings on transmission dynamics. Overall, the findings support immunity debt as an important mechanism underlying post-pandemic viral resurgence while demonstrating that epidemic recovery varies across pathogens according to their immunological characteristics and transmission dynamics. These results provide evidence to inform future public health preparedness and surveillance strategies for endemic infectious diseases. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2026-08-31T16:12:06Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2026-08-31T16:12:06Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員審定書 i
Acknowledgement ii 中文摘要 iv Abstract v Table of Contents vii List of Figures viii List of Tables x 1. Introduction 1 1.1 COVID-19 Pandemic, Non-Pharmaceutical Interventions, and Changes in Viral Transmission 1 1.2 Immunity Debt and Post-pandemic Resurgence of Endemic Viruses 2 1.3 Respiratory Syncytial Virus (RSV) 4 1.4 Erythema Infectiosum (Parvovirus B19) 7 1.5 Mathematical Transmission Models and Study Objectives 9 2. Methods 11 2.1 Study Design and Data Sources 11 2.2 Descriptive Age-Stratified Analysis 12 2.3 Transmission Model Overview 13 2.4 Force of Infection, Seasonality, and COVID-Associated Perturbation 14 2.5 RSV SIRS Models 15 2.6 Erythema Infectiosum SIR Model 17 2.7 Observation Model 17 2.8 Prior Distributions 18 2.9 Bayesian Estimation and Model Diagnostics 19 2.10 Interpretation of Post-Pandemic Resurgence 19 2.11 Wavelet Analysis 20 3. Results 20 3.1 RSV Epidemiological Characteristics in Tokyo 20 3.2 RSV Transmission Model (Tokyo) 24 3.3 RSV Transmission Model (Taiwan) 28 3.4 Comparison of RSV Epidemic Dynamics between Tokyo and Taiwan 32 3.5 Erythema Infectiosum Epidemiological Characteristics 34 3.6 Erythema Infectiosum Transmission Model 37 3.7 Wavelet Analysis of Epidemic Periodicity 41 3.8 Comparison Between RSV and Erythema Infectiosum in Tokyo 42 4. Discussion 43 References: 51 List of Figures Figure 1. SIRS model flow for RSV 15 Figure 2. SIR model flow for erythema infectiosum 17 Figure 3. Age-specific RSV epidemic curves in Tokyo from 2013 to 2025. 21 Figure 4. Monthly age composition of RSV cases in Tokyo from 2013 to 2025. 22 Figure 5. Age distribution of RSV cases before and after the COVID-19/NPI period in Tokyo 23 Figure 6. Age-specific RSV rebound ratio in Tokyo. 24 Figure 7. Observed and fitted weekly RSV cases in Tokyo from 2013 to 2025. 25 Figure 8. Estimated seasonal transmission profiles of RSV in Tokyo 26 Figure 9. Estimated COVID-associated transmission perturbation for RSV in Tokyo 27 Figure 10. Estimated susceptible (s), infectious (i), and recovered (r) population proportions from the RSV SIRS model (Tokyo) 28 Figure 11. Observed and fitted weekly RSV cases in Taiwan from 2019-2025 29 Figure 12. Estimated seasonal transmission profile for RSV in Taiwan 30 Figure 13. Estimated susceptible (s), infectious (i), and recovered (r) population proportions from the RSV SIRS model (Taiwan) 32 Figure 14. Comparison of observed and fitted weekly RSV cases in Tokyo and Taiwan from 2019 to 2025 33 Figure 15. Monthly age-specific epidemic curves of erythema infectiosum in Tokyo from 2013 to 2025 35 Figure 16. Monthly age composition of erythema infectiosum cases in Tokyo from 2013 to 2025 35 Figure 17. Age distribution of erythema infectiosum cases before and after the COVID-19/NPI period in Tokyo 36 Figure 18. Age-specific post-COVID rebound ratio of erythema infectiosum in Tokyo 37 Figure 19. Observed and fitted weekly erythema infectiosum cases in Tokyo from 2013 to 2025 38 Figure 20. Estimated seasonal transmission profile of erythema infectiosum in Tokyo 39 Figure 21. Estimated COVID-associated transmission perturbation for erythema infectiosum in Tokyo 39 Figure 22. Estimated susceptible (s), infectious (i), and recovered (r) proportions from the erythema infectiosum SIR model (Tokyo) 40 Figure 23. Wavelet power spectra of RSV (upper panel) and erythema infectiosum (lower panel) in Tokyo surveillance data 42 List of Tables Table 1. Comparison of epidemic characteristics 43 Table 2. Parameters for the Tokyo and Taiwan RSV SIRS models. (Priors were adapted from Park et al. (8) and modified for the present analysis.) 47 Table 3. Parameters for the Tokyo erythema infectiosum SIR model. (Priors were adapted from Park et al. (8) and modified for the present analysis.) 49 | - |
| dc.language.iso | en | - |
| dc.subject | COVID-19 | - |
| dc.subject | 非藥物介入措施 | - |
| dc.subject | 免疫負債 | - |
| dc.subject | 呼吸道融合病毒 | - |
| dc.subject | 傳染性紅斑 | - |
| dc.subject | SIRS | - |
| dc.subject | SIR | - |
| dc.subject | 隔間模型 | - |
| dc.subject | COVID-19 | - |
| dc.subject | non-pharmaceutical interventions | - |
| dc.subject | immunity debt | - |
| dc.subject | respiratory syncytial virus (RSV) | - |
| dc.subject | erythema infectiosum | - |
| dc.subject | SIRS | - |
| dc.subject | SIR | - |
| dc.subject | compartmental model | - |
| dc.title | COVID-19後的免疫負債與病毒再流行:呼吸道融合病毒與人類微小病毒B19 | zh_TW |
| dc.title | Post-COVID-19 Immunity Debt and Resurgent Viral Transmission: Respiratory Syncytial Virus and Parvovirus B19 | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 114-2 | - |
| dc.description.degree | 碩士 | - |
| dc.contributor.coadvisor | 林先和 | zh_TW |
| dc.contributor.coadvisor | Hsien-Ho Lin | en |
| dc.contributor.oralexamcommittee | 范怡琴;鄭皓元 | zh_TW |
| dc.contributor.oralexamcommittee | Yi-Chin Fan;Hao-Yuan Cheng | en |
| dc.subject.keyword | COVID-19; 非藥物介入措施; 免疫負債; 呼吸道融合病毒; 傳染性紅斑; SIRS; SIR; 隔間模型 | zh_TW |
| dc.subject.keyword | COVID-19; non-pharmaceutical interventions; immunity debt; respiratory syncytial virus (RSV); erythema infectiosum; SIRS; SIR; compartmental model | en |
| dc.relation.page | 53 | - |
| dc.identifier.doi | 10.6342/NTU202603394 | - |
| dc.rights.note | 同意授權(全球公開) | - |
| dc.date.accepted | 2026-08-05 | - |
| dc.contributor.author-college | 公共衛生學院 | - |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | - |
| dc.date.embargo-lift | 2026-09-01 | - |
| 顯示於系所單位: | 流行病學與預防醫學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-114-2.pdf | 2.3 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
